Pilot clinical trial of treatment with pioglitazone + metformin + flutamide versus Low-Dose Ethinyl Estradiol + cyproterone acetate as a control, in Adolescents with Ovarian Hyperandrogenism and Hyperinsulinism: Effects on Parameters of Chronic Inflammation, Type 2 Diabetes and cardiovacular risk [Ensayo clinico piloto de tratamiento con Pioglitazona+Flutamida+Metformina a Dosis Bajas versus Etinil-Estradiol + Acetato de Ciproterona como control, en Adolescentes con Hiperandrogenismo Ovarico e Hiperinsulinismo: Efectos sobre Parametros de Inflamacion Cronica, Diabetes Tipo 2 y Riesgo Cardiovacular]

Trial Profile

Pilot clinical trial of treatment with pioglitazone + metformin + flutamide versus Low-Dose Ethinyl Estradiol + cyproterone acetate as a control, in Adolescents with Ovarian Hyperandrogenism and Hyperinsulinism: Effects on Parameters of Chronic Inflammation, Type 2 Diabetes and cardiovacular risk [Ensayo clinico piloto de tratamiento con Pioglitazona+Flutamida+Metformina a Dosis Bajas versus Etinil-Estradiol + Acetato de Ciproterona como control, en Adolescentes con Hiperandrogenismo Ovarico e Hiperinsulinismo: Efectos sobre Parametros de Inflamacion Cronica, Diabetes Tipo 2 y Riesgo Cardiovacular]

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2012

At a glance

  • Drugs Flutamide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Ethinylestradiol/cyproterone
  • Indications Ovarian hyperstimulation syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Jul 2012 Status changed from recruiting to completed.
    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top